http://www.niaid.nih.gov/news/newsrelea ... pevac.aspx Study
Finds Genital Herpes Vaccine Ineffective in Women An
experimental vaccine intended to prevent genital herpes disease
in women, although generally safe and well-tolerated, proved
ineffective when tested in the recently concluded clinical study
known as the Herpevac Trial for Women. The Phase 3 trial,
sponsored by GlaxoSmithKline (GSK) Biologicals, based in
Belgium, with support from the National Institute of Allergy and
Infectious Diseases (NIAID), part of the National Institutes of
Health, began in 2002. A total of 8,323 women aged 18-30 years
participated in the trial at 50 sites in the United States and
Canada. At the time of their enrollment, the study participants
were free of the two types of herpes simplex viruses (HSV),
HSV-1 and HSV-2. Participants in the Herpevac trial were
randomly divided into two groups. One group received the
candidate vaccine, containing HSV protein along with an adjuvant
intended to boost immune responses. The second,